image: ARDD 2026
Credit: ARDD
BOSTON, MA — Aug 5, 2026 — Insilico Medicine and the ARDD organizing committee are pleased to announce that Fiona Marshall, President of Biomedical Research at Novartis will deliver a featured talk “Reimagining Drug Discovery Through the Lens of Aging Biology” at the 13th Aging Research & Drug Discovery (ARDD) Meeting. This landmark event will take place from October 1-3, 2026, at the David Rubenstein Treehouse at Harvard University.
As longevity science transitions from theoretical concepts to multi-billion-dollar therapeutic pipelines, ARDD 2026 stands as the premier global nexus connecting basic science, clinical research, big pharma, and institutional investors.
"As scientists, there’s nothing more fulfilling than seeing our discoveries translate into meaningful medicines for patients, said Fiona Marshall, President of Biomedical Research at Novartis. Our research teams are committed to this mission. By building on our strengths, including our long history of scientific innovation and technological leadership, we aim to deliver the next generation of medicines that will make a real difference to people’s lives."
As longevity science transitions from theoretical concepts to multi-billion-dollar therapeutic pipelines, ARDD 2026 stands as the premier global nexus connecting basic science, clinical research, big pharma, and institutional investors.
"The biology of aging has become one of the most promising frontiers in biomedical science. Our challenge is to both better understand it and translate fundamental discoveries into interventions that improve healthspan. That will require an unprecedented level of collaboration across disciplines and sectors,” said Vadim Gladyshev, Executive Chair of ARDD and Professor of Medicine at Harvard University. Conferences like ARDD play an important role by bringing together the people who can ask difficult questions, test new ideas, and build the partnerships needed to advance the field."
Having visionary presenters share their insights alongside leaders from ten of the world's top pharmaceutical companies ensures that ARDD 2026 will be an unmatched catalyst for translating longevity science into real-world medicine.
“ARDD has always been about bringing together the world's leading minds in aging research to accelerate the development of interventions that extend healthy lifespan," said Morten Scheibye-Knudsen, Co-Chair of ARDD and Associate Professor at the University of Copenhagen. Moving ARDD to Boston marks an exciting new chapter, placing the conference at the heart of one of the world's strongest biomedical innovation ecosystems. At the same time, ARDD 2026 reflects the field's increasing maturity, with an incredibly strong focus on translating scientific discoveries into medicines. The future is bright.”
Officially organized by Insilico Medicine, the 2026 meeting is anchored by Tier 1 sponsors Insilico Medicine and Eli Lilly, with the McKinsey Health Institute joining as the Sole Knowledge Partner. The conference brings together a highly curated ecosystem of academic leaders, biotechnology innovators, pharmaceutical companies, entrepreneurs, and investors, including Tier 3 sponsors AbbVie, AniVC, AstraZeneca, BioAge Labs, Biocytogen, Cambrian Bio, Cyclarity Therapeutics, Dior, GlycanAge, Gordian Biotechnology, Human Longevity, Institute for Healthier Living Abu Dhabi, LongeVC, Maxwell Biosciences, Nestlé, Tally Health, and TruDiagnostic. Synaro Capital, The Cat Health Company, and PranaGen Bioscience support the event as Tier 4 sponsors, alongside Tier 5 sponsors Morgan Stanley, the Intrinsic Capacity Frailty & Sarcopenia Research Conference for Healthy Longevity, and QuadraScope.
“For over a decade, ARDD has served as the primary global platform for academia-pharma-startup-investor dialogue,” said Alex Zhavoronkov, Ph.D., Co-Chair of ARDD and CEO of Insilico Medicine. “The massive momentum driving this year's meeting in Boston underscores that longevity biotechnology has become a foundational pillar of modern drug discovery and health economics.”
For more information or interview requests with speakers, please contact: ardd@pharma.ai
About the Aging Research & Drug Discovery (ARDD) Meeting
The Aging Research & Drug Discovery (ARDD) Meeting is the world's largest meeting dedicated to aging and longevity biotechnology. Now in its 13th year, ARDD brings together researchers, clinicians, biotechnology and pharmaceutical leaders, entrepreneurs, investors, and policymakers from around the world to accelerate the translation of breakthroughs in the biology of aging into practical R&D and therapeutic programs. The 2026 meeting will take place October 1–3 at the David Rubenstein Treehouse at Harvard University in Boston. Learn more at agingpharma.org.
The Nordic Aging Society is a supporter of ARDD and a non-profit scientific organization dedicated to advancing research on the biology of aging and promoting collaboration among researchers, clinicians, and industry across the Nordic region and beyond.